Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director · Chief Executive Officer | July 08, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Syndax Pharmaceuticals Inc
Report date July 08, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 484,843 |
Ending reported balance
After 2026-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 517,218 Row 2 · 2026-07-08 · Sale · Disposed 32,375 · Balance 484,843 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested. F2: The sale prices ranged from $24.00 to $24.43 |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2026-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 0 F3: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested.
F2: The sale prices ranged from $24.00 to $24.43
F3: This option is fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 63,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)
F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 2,045 | $19.05 | $38,963.79 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $19.00 to $19.49. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 2,045 | $7.20 | $14,724.00 |
DisclosureSEC source: 0001562180-21-007710 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 16,296 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,296 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 16,296 | $19.20 | $312,824.53 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F3 · price: The sales price ranged from $19.01 to $19.33 Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 16,296 | $7.20 | $117,331.20 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 44,704 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,704 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 44,704 | $19.13 | $855,335.04 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The share price ranged from $19.00 to $19.48 Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 44,704 | $7.20 | $321,868.80 |
DisclosureSEC source: 0001562180-21-006652 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:36 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 24,437 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006136 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,437 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:36 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 24,437 | $19.51 | $476,831.85 |
DisclosureSEC source: 0001562180-21-006136 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sales price ranged from $19.02 to $19.96 Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:36 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 24,437 | $7.20 | $175,946.40 |
DisclosureSEC source: 0001562180-21-006136 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 300 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · derivative · entry 9 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 22, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 300 | $19.02 | $5,706.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F4 · price: The sale prices ranged from $19.00 to $19.06 Read SEC document |
| September 22, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 300 | $7.20 | $2,160.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,808 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · derivative · entry 8 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,808 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 4,808 | $19.16 | $92,108.30 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F3 · price: The sale prices ranged from $19.02 to $19.31 Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 4,808 | $7.20 | $34,617.60 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 31,455 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · derivative · entry 7 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,455 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 31,455 | $19.24 | $605,046.36 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sale price ranged from $19.00 to $19.92 Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 31,455 | $7.20 | $226,476.00 |
DisclosureSEC source: 0001562180-21-006060 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 44,349 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,349 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 44,349 | $19.15 | $849,394.22 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F3 · price: The sale prices ranged from $19.00 to $19.31 Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 44,349 | $7.20 | $319,312.80 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 16,651 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,651 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 16,651 | $19.02 | $316,638.75 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sale prices ranged from $19.00 to $19.10 Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 16,651 | $7.20 | $119,887.20 |
DisclosureSEC source: 0001562180-21-005948 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 18:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-21-011373 · doc4.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-10 F1 · derivative.exercise_date: This stock option was granted on March 10, 2021 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2022 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. The stock option is subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:22 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001562180-21-000935 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 15,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-21-000869 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 15,000 | $20.19 | $302,799.00 |
DisclosureSEC source: 0001562180-21-000869 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 732,490 options to purchase shares of common stock that are vested and immediately exercisable and a total of 343,750 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.00 to $20.44. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:53 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 15,000 | $7.20 | $108,000.00 |
DisclosureSEC source: 0001562180-21-000869 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-20-007070 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 15,000 | $22.97 | $344,512.50 |
DisclosureSEC source: 0001562180-20-007070 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 705,824 options to purchase shares of common stock that are vested and immediately exercisable and a total of 565,416 options to purchase shares of common stock that have not yet vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 15,000 | $7.20 | $108,000.00 |
DisclosureSEC source: 0001562180-20-007070 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 100,000 | $20.31 | $2,031,410.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 18:31 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantNon-qualified Stock Option · Derivative | 126,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000891293-20-000013 · primary_doc.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common stock · 126,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: This stock option was granted on March 11, 2020 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2021 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. The stock option is subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001238 · primarydocument.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-02-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001238 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · shares: 3,750 shares shall vest on each of 02/12/2021, 02/12/2022, 02/12/2023 and 02/12/2024. Read SEC document |
| July 04, 2019 Filed Jul 8, 2019 20:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001562180-19-003880 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-07-04 F1 · derivative.exercise_date: The securities awarded on 07/04/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan and shall vest in 48 successive equal monthly installments measured from 07/04/2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:11 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-19-000045 · primary_doc.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2020 at which one or members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000852 · primarydocument.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2029-02-06 F2 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 120,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 120,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| January 31, 2019 Filed Feb 8, 2019 21:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 2,659 | $4.76 | $12,656.84 |
DisclosureSEC source: 0001562180-19-000852 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,659 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,659 shares by the Reporting Person on 01/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:55 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000891293-18-000063 · primary_doc.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: This stock option was granted on May 17, 2018 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2019 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-18-001425 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018. Read SEC document |
| January 20, 2018 Filed Jan 22, 2018 18:28 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | Exercise / conversionRestricted Stock Unit · Derivative | 20,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000891293-18-000005 · primary_doc.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.exercise_date: This restricted stock unit was granted on January 20, 2017 and vested on January 20, 2018. F2 · derivative.expiration_date: This restricted stock unit was granted on January 20, 2017 and vested on January 20, 2018. Read SEC document |
| January 20, 2018 Filed Jan 22, 2018 18:28 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | Exercise / conversionCommon Stock | 20,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000891293-18-000005 · primary_doc.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 17:30 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0000899243-17-005428 · doc4.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: This stock option was granted on February 23, 2017 and vests on the first to occur of (i) the date that is twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2018 at which one or more members of the CTIC Board of Directors are to be elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2015 Equity Incentive Plan), subject to the Reporting Persons' continued service through such date or event. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-17-000567 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-02-06 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.